Immune Checkpoint Inhibitor, Cytotoxic T lymphocyte associated-4 Inhibitor, CTLA-4 inhibitor, Ipilimumab, Yervoy, Programmed Cell Death Protein 1 Inhibitor, PD-1 Inhibitor, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Programmed death ligand-1 Inhibitor, PDL-1 Inhibitor, Atezolizumab, Tecentriq, Avelumab, Bavencio, Durvalumab, Imfinzi